Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

Table 1 Clinical status and profile of the patients

	KIF20A peptide vaccine treatment	Best supportive care
	Chiba (n = 31) *	Chiba (n = 9) *	Multi-center (n = 81) **
Age (average, (range))	61.3 (33–80)	64 (53–82)	64.5 (41–85)
Sex (Male: Female)	17:14	5:4	49:32
Performance status (0:1:2:3)	11:8:12:0	1:3:3:2	13:28:36:0 ***
Status of primary lesion (Resected: Unresected)	15:16	1:8	23:58
Median survival time (days)	142.0 ± 23.7	83.0 ± 33.5	62.0 ± 6.5
Mean survival time (days)	171.8 ± 23.8	93.3 ± 14.8	91.1 ± 11.6

*, Clinical data obtained at our institution, Chiba Tokushukai Hospital.
**, Clinical data of Multi-center (n = 81) include those obtained from Chiba and other three hospitals.
***, 4 cases were excluded, since Performance Status was not determined.

ISSN: 1479-5876